Ceralasertib

Generic Name
Ceralasertib
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C20H24N6O2S
CAS Number
1352226-88-0
Unique Ingredient Identifier
85RE35306Z
Background

Ceralasertib is under investigation in clinical trial NCT03682289 (Phase II Trial of AZD6738 Alone and in Combination With Olaparib).

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Phase 1
Active, not recruiting
Conditions
Chronic Lymphocytic Leukemia
Interventions
Drug: Ceralasertib
Drug: Acalabrutinib
First Posted Date
2017-11-01
Last Posted Date
2024-11-19
Lead Sponsor
Acerta Pharma BV
Target Recruit Count
11
Registration Number
NCT03328273
Locations
πŸ‡¬πŸ‡§

Research Site, Southampton, United Kingdom

A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).

First Posted Date
2017-01-16
Last Posted Date
2021-08-10
Lead Sponsor
AstraZeneca
Target Recruit Count
21
Registration Number
NCT03022409
Locations
πŸ‡¨πŸ‡³

Research Site, Taipei, Taiwan

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors

First Posted Date
2016-06-24
Last Posted Date
2023-05-30
Lead Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Target Recruit Count
460
Registration Number
NCT02813135
Locations
πŸ‡©πŸ‡°

Rigshospitalet, Copenhagen, Denmark

πŸ‡«πŸ‡·

Gustave Roussy, Villejuif, Val De Marne, France

πŸ‡³πŸ‡±

Erasmus MC, Sophia Children's Hospital, Rotterdam, Netherlands

and more 4 locations
Β© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy